Little House Capital LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Little House Capital LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 34.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,891 shares of the company's stock after buying an additional 1,266 shares during the period. Eli Lilly and Company accounts for about 1.1% of Little House Capital LLC's holdings, making the stock its 29th largest holding. Little House Capital LLC's holdings in Eli Lilly and Company were worth $4,040,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Eli Lilly and Company by 0.8% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,953,449 shares of the company's stock worth $1,613,373,000 after buying an additional 16,319 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 9.1% in the 1st quarter. Golden State Wealth Management LLC now owns 1,019 shares of the company's stock valued at $842,000 after purchasing an additional 85 shares during the last quarter. Patron Partners LLC lifted its holdings in shares of Eli Lilly and Company by 4.4% in the 1st quarter. Patron Partners LLC now owns 3,718 shares of the company's stock valued at $3,071,000 after purchasing an additional 157 shares during the last quarter. Confluence Wealth Services Inc. lifted its holdings in shares of Eli Lilly and Company by 17.3% in the 1st quarter. Confluence Wealth Services Inc. now owns 10,315 shares of the company's stock valued at $8,555,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Bordeaux Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 84.2% in the 1st quarter. Bordeaux Wealth Advisors LLC now owns 2,199 shares of the company's stock valued at $1,816,000 after purchasing an additional 1,005 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. UBS Group reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.61.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $776.18 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The stock's 50-day moving average price is $780.19 and its 200 day moving average price is $800.08. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The stock has a market capitalization of $735.61 billion, a PE ratio of 63.16, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the company earned $2.58 EPS. The company's revenue was up 45.2% on a year-over-year basis. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.